Extracellular Vesicles-Based Liquid Biopsy Market Size, Share and Trends 2025 to 2034

Revenue, 2024

USD 120.04 Mn

Forecast Year, 2034

USD 149.66 Mn

CAGR, 2025 - 2034

2.23%

Report Coverage

Global

What is the Extracellular Vesicles-Based Liquid Biopsy Market Size?

The global extracellular vesicles-based liquid biopsy market size is calculated at USD 122.72 million in 2025 and is predicted to increase from USD 125.45 million in 2026 to approximately USD 149.66 million by 2034, expanding at a CAGR of 2.23% from 2025 to 2034. This market is growing due to the increasing demand for minimally invasive diagnostic tools and the rising global prevalence of cancer.

Market Highlights

• North America dominated the market, holding the largest market share of 48.40% in 2024.
• The Asia Pacific is expected to expand at the fastest CAGR of 15.5% between 2025 and 2034.
• By type of vesicle, the exosomes segment held the major market share of 54.3% in 2024.
• By type of vesicle, the apoptotic bodies segment is expected to grow at a remarkable CAGR of 14.2% from 2025 to 2034.
• By component, the kits & reagents segment contributed the highest market share of 54.4% in 2024.
• By component, the services segment is growing at a remarkable CAGR of 14.4% from 2025 to 2034.
• By application, the oncology segment recorded the highest market share of 48.2% in 2024.
• By application, neurology is growing at a remarkable CAGR of 14.8% between 2025 and 2034.
• By biomarker type, the RNA biomarkers segment accounted for the highest market share of 51.8% in 2024.
• By biomarker type, the DNA biomarkers segment is expected to expand at a solid CAGR of 14.6% between 2025 and 2034.
• By end user, the academic & research institutes segment held the largest market share of 46.5% in 2024.
• By end user, the hospitals & diagnostic centers segment is set to grow at a significant rate of 14.7% CAGR between 2025 and 2034.

Market Overview

EV-Based Liquid Biopsy: Transforming Diagnostics for Precise, Early Detection

The extracellular vesicle-based liquid biopsy market is expanding rapidly as demand for precise, non-invasive diagnostic tools increases. For early disease detection, particularly in cancer, EVs offer rich biomarker data. Due to advanced R&D, North America dominates the market, while the Asia Pacific exhibits robust growth supported by healthcare investments. Wider adoption is still constrained by issues like standardization and high costs.

Case Study: In June 2024, Mursla Bio launched NEXOS, an advanced electro-optical extracellular vesicle (EV) detection system designed for ultra-sensitive diagnostics. The technology combines electrical and optical detection methods to quantify EV subtypes and protein markers in blood with unprecedented precision. This innovation supports non-invasive liquid biopsy applications, particularly in early cancer detection and precision medicine . NEXOS also underpins Murslas EvoLive program for liver cancer surveillance, which has received FDA Breakthrough Device Designation for its strong diagnostic performance.

Key Technological Shifts & Innovation in Extracellular Vesicles-Based Liquid Biopsy Market

Extracellular Vesicles-Based Liquid Biopsy Market Outlook

[[market_outlook]]

Market Scope

Extracellular Vesicles-Based Liquid Biopsy Market Segmental Insights

[[segment_insights]]

Extracellular Vesicles-Based Liquid Biopsy Market Regional Insights

[[regional_insights]]

Extracellular Vesicles (EV)-Based Liquid Biopsy Market Value Chain

[[value_chain]]

Extracellular Vesicles-Based Liquid Biopsy Market Companies

[[market_company]]

Other Players in the Extracellular Vesicles-Based Liquid Biopsy Market

• Bio-Techne Corporation: Bio-Techne develops and manufactures high-quality biological research materials, instruments, and diagnostic solutions. Through its subsidiary Exosome Diagnostics, the company offers advanced extracellular vesicle (EV) isolation and analysis platforms for liquid biopsy applications, enabling biomarker discovery and cancer diagnostics.
• Illumina, Inc .: Illumina is a global leader in DNA sequencing and genomic analysis technologies that play a critical role in EV-based liquid biopsy workflows. Its sequencing platforms are used for profiling exosomal RNA and DNA, facilitating precision oncology, early disease detection, and personalized medicine .
• NanoView Biosciences, Inc: NanoView Biosciences specializes in single-exosome characterization technology. Its ExoView platform provides high-resolution, label-free detection and quantification of individual extracellular vesicles, supporting biomarker discovery and clinical assay development in liquid biopsy research.
• Norgen Biotek Corp.: Norgen Biotek provides comprehensive sample preparation kits and nucleic acid purification systems optimized for exosome and EV isolation. The companys products enable efficient RNA, DNA, and protein extraction from biofluids, supporting both clinical diagnostics and research applications.
• System Biosciences, LLC: System Biosciences offers research tools and kits for exosome isolation, RNA analysis, and EV labeling. The companys proprietary ExoQuick platform is widely used for scalable exosome purification and downstream molecular profiling.
• Beckman Coulter, Inc. (Danaher Corporation): Beckman Coulter provides automated centrifugation and flow cytometry solutions essential for exosome isolation, quantification, and analysis. Its instruments support high-throughput workflows in EV-based diagnostics and research laboratories.
• Hitachi Chemical Diagnostics, Inc: Hitachi Chemical Diagnostics develops diagnostic solutions incorporating EV biomarkers for cancer and neurological disease detection. The company focuses on combining advanced chemical analysis with EV isolation for improved diagnostic sensitivity.
• Exosome Diagnostics (Bio-Techne subsidiary): Exosome Diagnostics, a subsidiary of Bio-Techne, offers liquid biopsy tests based on exosome-derived RNA and DNA analysis. Its proprietary ExoLution technology enables non-invasive detection of cancer biomarkers from biofluids such as blood and urine.
• HansaBioMed Life Sciences: HansaBioMed Life Sciences specializes in EV isolation products, antibodies, and analytical tools. The companys kits and standards are used globally in exosome research, offering solutions for quality control, size profiling, and molecular analysis.
• Evox Therapeutics Ltd.: Evox Therapeutics develops engineered exosome-based delivery platforms for targeted drug and RNA therapy. Its proprietary technology leverages natural EV pathways for precise molecular transport, contributing to innovations in EV-based diagnostics and therapeutics.
• Miltenyi Biotec: Miltenyi Biotec provides advanced EV isolation and analysis solutions, including magnetic separation and flow cytometry systems. Its MACS technology allows for high-purity exosome enrichment from complex biological fluids, supporting translational research and biomarker validation.
• Lonza Group AG: Lonza offers manufacturing and analytical services for extracellular vesicle-based products. The company supports EV purification, characterization, and scalable production for diagnostic developers and biopharmaceutical companies working on EV therapeutics.
• NanoSomix, Inc.: NanoSomix focuses on developing non-invasive liquid biopsy tests based on exosome and EV biomarkers for neurological and neurodegenerative diseases. Its diagnostic research targets Alzheimers and Parkinson disease, utilizing circulating vesicle signatures for early detection.

Extracellular Vesicles-Based Liquid Biopsy MarketSegments Covered in the Report

[[segment_covered]]